All sponsors

Vir Biotechnology, Inc. $VIR

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-20
ACTIVE TRIALS5
PHASE 3 / 2-32
RECRUITING1
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO60%

Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +15.7 months). See all sponsors →

Open Vir Biotechnology, Inc. on the live radar map → 📅 $VIR readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Tobevibart
NCT06903338
P3Active, not recruitingViral Hepatitis1242026-09-30 (-3 mo)
Tobevibart
NCT07128550
P3Active, not recruitingViral Hepatitis1502026-12
VIR-5818
NCT05356741
P1/2RecruitingLocally Advanced or Metastatic HER2-Expressing Cancers6452028-04 (+16 mo)
Tobevibart
NCT07142811
P2Active, not recruitingViral Hepatitis1002029-03 (+28 mo)
VIR-2218
NCT05461170
P2Active, not recruitingHepatitis D, Chronic952031-11 (+59 mo)